1
4
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TN1195 |
17-Hydroxy sprengerinin C
17-羟基麦冬皂苷C |
BCL; Others; Caspase | Apoptosis; Others; Proteases/Proteasome |
17-Hydroxy sprengerinin C 是从黄精的根茎中分离得到的一种糖苷化合物,具有更强的抗癌活性。17-Hydroxy sprengerinin C 降低 Blc-2 和 pro-caspase3 的表达并增加 Bax 的产生。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-00423 |
FGFR2 Protein, Human, Recombinant (alpha IIIb, hFc)
BFR-1,KGFR,TK25,JWS,ECT1,K-SAM,FGFR2 α(IIIb),C<... |
Human | HEK293 Cells |
FGFR2 Protein, Human, Recombinant (alpha IIIb, hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 66.3 kDa and the accession number is P21802-17. | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |